Italy Diabetes Market Report 2026 | Growth, Trends, and Forecast by 2034

Market Overview

The Italy diabetes market was valued at USD 1,168.6 Million in 2025 and is expected to reach USD 1,598.7 Million by 2034, expanding steadily. The forecast period from 2026 to 2034 reflects a growth rate 3.44% driven by the rising prevalence of Type 2 diabetes, a rapidly aging population, broad coverage of the Italian National Healthcare Service (SSN) reimbursement and increasing adoption of GLP-1 therapies. Retail pharmacies hold the largest distribution share at 52.4%, while oral antidiabetics dominate the market segment with 56.3% share.

How AI is Reshaping the Future of Italy Diabetes Market:

• AI-enabled dose titration platforms are extending diabetes care beyond clinics, facilitating real-time dose adjustments.

• Integration of continuous glucose monitors with smart insulin pens and smartphone apps allows automated insulin dosing and remote physician oversight.

• Digital therapeutics powered by AI support behavior-change mobile applications and tele-consultation tools, improving patient adherence.

• Tele-pharmacy platforms, supported by Italy’s digital prescription reforms, enable online chronic medication refills and home delivery.

• AI-driven automation in pharmacies streamlines chronic refill management through integrated e-prescription systems.

Grab a sample PDF of this report: https://www.imarcgroup.com/italy-diabetes-market/requestsample

Market Growth Factors

The rising prevalence of Type 2 diabetes in Italy is a key driver, fueled by lifestyle changes, obesity, and sedentary behavior, which collectively increase the patient base demanding effective treatment options. This increase directly contributes to market expansion as documented in the report, supporting higher volumes of both oral antidiabetics and insulin therapies. The broad reimbursement coverage by the Italian National Healthcare Service (SSN) ensures that insured patients receive medicines, devices, and specialist visits with no out-of-pocket cost, supporting strong adherence and continuous therapy access across all Italian regions. This universal coverage enhances the market stability and growth in the Italy type 1 diabetes treatment market as well.

The rapid adoption of GLP-1 receptor agonists also propels the market by offering advanced clinical benefits, including weight reduction and cardiovascular outcomes, leading physicians to prefer drugs like semaglutide, tirzepatide, and dulaglutide over older agents. These therapies are gaining traction in insulin-naive patients, reshaping therapeutic patterns and boosting sales volumes for oral antidiabetics. Oral antidiabetics lead market segmentation, reflecting this shift driven by GLP-1 and SGLT-2 inhibitors combined usage in the Italy type 1 diabetes treatment market.

Italy's rapidly aging population further drives market growth, with diabetes prevalence climbing significantly in the 65+ age group. Italy holds the highest share of older adults in the EU, expanding the chronic therapy patient pool served by retail and hospital pharmacies. Retail pharmacies dominate distribution channels, supported by dense community coverage and patient preference for in-person counseling. This demographic trend necessitates increased medication demand and specialized care services, further driving market expansion in the Italy type 1 diabetes treatment market.

Market Segmentation

Market Segmentation

• By Segment

• Oral Antidiabetics

• Insulin

• By Distribution Channel

• E-commerce and Tele-pharmacy

• Hospital Pharmacies

• Retail Pharmacies

Key Players

• Novo Nordisk A/S

• Sanofi

• AstraZeneca

• Boehringer Ingelheim International GmbH.

• Novartis AG

Recent Developement & News

• July 2025: The Italian government appointed a special commissioner to accelerate Novo Nordisk's over EUR 2 Billion investment for expanding its manufacturing facility in Anagni, Frosinone, enhancing supply for GLP-1 therapies and insulin products.

• August 2024: Sanofi initiated a EUR 1.3 Billion expansion of its Frankfurt facility, ensuring supply continuity for long-acting insulin treatments critical for Italian diabetes patients.

• 2024: Italian public expenditure on antidiabetic drugs increased to EUR 1.642 Billion, a 13.2% rise over the previous year, reflecting increased demand and treatment coverage.

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302